CLLS cellectis.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת
The market trend for Cellectis S.A. (CLLS) shares on the GURU.Markets platform, where the EV/EBITDA multiple is 0.00, is based on reliable express delivery of biomaterials under cryogenic conditions. The business relies on the unique TALEN gene-editing system, which ensures technological superiority in oncology treatment. Development is supported by the UCEL plant, where sterile lines are being expanded for new clinical trials.
cellectis.com (CLLS) - פילוחי מדדים ודוחות פיננסיים
The stability of Cellectis S.A. (CLLS) is supported by the protected nature of its oncology therapy developments, which mitigates geopolitical conflict risks. Operating within the legal frameworks of the EU and US ensures predictable cash flows. The company's EV/EBITDA ratio on this chart compares market value with debt and operating profit, revealing the actual efficiency of capital management. The dynamics of this metric allow investors to distinguish the fundamental value of the business from temporary market fluctuations.
